VOYAGER PAD Trial Summary The VOYAGER PAD trial aimed to assess the efficacy and safety of rivaroxaban, a factor Xa inhibitor, in patients with peripheral artery disease (PAD) who had undergone lower-extremity revascularization. Patients with PAD who have undergone revascularization are at a high risk of major adverse limb and cardiovascular events, but the role […]